© 2017 Pharmstandard Ventures
Proteon Therapeutics
(NASDAQ:PRTO)
Waltham, MA, USA
Year of Investment: 2014
(NASDAQ:PRTO)
Waltham, MA, USA
Year of Investment: 2014
IPO in October, 2014
Proteon Therapeutics
(NASDAQ:PRTO)
Waltham, MA, USA
Year of Investment: 2014
(NASDAQ:PRTO)
Waltham, MA, USA
Year of Investment: 2014
IPO in October, 2014
Proteon Therapeutics Inc. is a biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. Proteon's first drug candidate, PRT-201, is a locally-acting recombinant human elastase that fragments elastin fibers in blood vessel walls, thus improving the maturation, patency and life of arteriovenous fistula in hemodialysis patients.
For more information, please visit:
www.proteontherapeutics.com
For more information, please visit:
www.proteontherapeutics.com
Proteon Latest News
10.01.2020
ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics
23.09.2019
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
Read more news >
10.01.2020
ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics
23.09.2019
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
Read more news >
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally